Secondary immunodeficiencies are becoming more common as they can develop in the course of numerous diseases and result from a variety of therapeutic procedures including allogeneic hematopoietic stem cell transplantation, solid organ transplantations and biological therapies, especially B cell depleting therapies, which have been recently used with increasing frequency. Although the problem is very important, consensus guidelines on the indications, regimens and monitoring of the immunoglobulin replacement therapy in this group patients are lacking. Therefore, it is necessary to perform epidemiological assessment of the frequency of secondary immunodeficiency disorders in Poland and to make the best use of the experience gained in other countries in the field of the immunoglobulin replacement therapy including eligibility criteria, dosage regimens and duration of treatment and to combine them with cost-effectiveness analysis. Provision patients with the opportunity of home treatment with subcutaneous immunoglobulin, which has proven highly beneficial in patients with primary immunodeficiency disorders, seems to be of key importance.